

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PCT/DO-EO
Commissioner for Patents
Washington, DC 20231

"Express Mail" mailing label number **EL 823 533 194 US**

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 CFR § 1.10 on the date indicated above and addressed to: **BOX PCT/DO-EO**, Commissioner for Patents, Washington, DC 20231 on December 13, 2001.


Colleen Hanagan

NATIONAL STAGE APPLICATION TRANSMITTAL LETTER
APPLICATION FILING UNDER 35 U.S.C. § 371

Transmitted herewith for filing is the patent application of:

Inventor(s)/Applicant(s): **Thonnard, Joelle**
International Application No.: **PCT/EP00/05852**
International Published Appln. No.: **WO 01/00837**
International Filing Date: **23 June 2000**
Priority Filing Dates: **25 June 1999**
Thirty Month Date: **25 December 2001**
Title: **"BASB111 POLYPEPTIDE AND
POLYNUCLEOTIDE FROM
MORAXELLA CATARRHALIS"**

1. **THIS NEW APPLICATION IS A NATIONAL STAGE
APPLICATION UNDER PCT, CHAPTER II WITH A REQUEST FOR
EXAMINATION WITHOUT DELAY TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US).**

This is a **FIRST** submission of items concerning a filing under 35 U.S.C. § 371;

This is a **SECOND** or subsequent submission of items concerning a filing under 35 U.S.C. § 371.

2. This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).

531 Rec'd PCT 13 DEC 2001

3. A proper Demand for International Preliminary Examination was made by the 19TH month from the earliest claimed priority date.

4. Enclosed items are required for filing under 37 CFR § 1.53(b) and § 1.494(b) or § 1.495(b):

- One copy of International Publication No. WO 00/00837
- (a) is transmitted herewith (**required only if not transmitted by the International Bureau**)
- (b) has been transmitted by the International Bureau
- (c) is not required, as the application was filed in the United States Receiving Office (RO/US)

Fees

The basic national fee set forth in 37 CFR § 1.482 - International Preliminary Examination Fee not paid to USPTO but International Search Report prepared by the EPO or JPO - \$890.00

- Claims in Excess of 20 (3 @ \$18.00)
- Independent Claims in Excess of 3 (@ \$84.00)

5. Further enclosed are:

- One copy of International Preliminary Examination Report.
- One copy of International Search Report.
- One copy of Written Opinion.
- One copy of PCT Request as filed.
- One copy of Chapter II Demand as filed.

6. A translation of the International Application into English (35 U.S.C. § 371(c)(2))

7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. § 371(c)(3))

8. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. § 371(c)(3))

9. Still additional papers enclosed:

- Assignment with Assignment Recordation Form Cover Sheet
- Verification Statement Claiming Small Entity Status
- Declaration or oath is enclosed executed by the inventor
- An Information Disclosure Statement under 37 CFR § 1.97 and § 1.98
- Return Acknowledgment Postcard

531 Rec'd PCT 13 DEC 2001

10. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)

A. Enclosed are:

(a) Computer Readable Copy of the Sequence Listing

(b) Paper Copy (identical to Computer Readable Copy) of the Sequence Listing

B. Enclosed is a paper copy of the Sequence Listing. This paper copy and a Computer Readable Form thereof are identical with the Computer Readable Form in another application of the Applicant which is fully identified as follows:

U.S. Application No.: @@

Filed: @@

Attorney Docket No.: @@

which is believed to comply with the rules set forth in 37 CFR § 1.821 et. seq. Applicants requests pursuant to 37 CFR § 1.821(e) that this Computer Readable Form be used in the present application. **Please TRANSFER the sequence listing from the parent to this application.**

C. Statement under 37 CFR § 1.821(f): **The information recorded in computer readable form is identical to the written Sequence Listing.**

D. Statement under 37 CFR § 1.821(g) (required when Sequence Listing not submitted at the time of filing under 35 U.S.C. §111(a)) or 37 CFR §1.821(f) (required when Sequence Listing not submitted at the time of filing under the Patent Cooperation Treaty): **The submission of the Sequence Listing includes no new matter.**

E. Amendment: Please enter the Sequence Listing into the application.

11. **Preliminary Amendment**

Prior to calculation of fees, kindly enter:

Preliminary Amendment submitted herewith

do not enter Preliminary Amendment

12. The correspondence address for this application is the Customer No. provided below:

Insert Bar Code Label Here:



25308


PATENT TRADEMARK OFFICE

13. Fee payment being made at this time is enclosed:

* Basic filing fee (\$890.00)	890.00
* Claims in Excess of 20	54.00
* (3 @ \$18.00)	
Independent Claims in Excess of 3 (@ \$84.00)	00.00
* Total Fees enclosed:	<u>\$944.00</u>

14. The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Account No. 50-0258. This letter is filed in duplicate for accounting purposes.

Respectfully submitted,


 Teresa O. Bittenbender
 Registration No. 47,425
 Attorney for Applicant

DECHERT
 1717 Arch Street
 4000 Bell Atlantic Tower
 Philadelphia, PA 19103
 Fax: (215) 994-2222
 Attn.: Teresa O. Bittenbender, Esq.
 (215) 994-2213

123878.1.07